Regenerative Precision Medicine for Chronic Inflammation
Integrating medical power and biological precision by generative AI
The unsolved challenge of future medicine is either chronic inflammatory disease (CID) or tumor. Two-thirds of this challenge consists of chronic inflammation. Thus far, biomarker- and AI-driven development has just empowered tumor treatment. None of this has been available for chronic inflammatory disease.
Until now. There is now a solution. We have it.
Strategic & meaningful partnerships
Precision medicine for Chronic Inflammation
Transgenion, a Spin-off of the Medical University of Vienna, is a pharmaceutical Research and Development Company established in 2015 based on the unprecedented success of more than twenty years of translational research by Prof. Rolf Ziesche and his team in Vienna, supported by both national and EU funding.
Transgenion realizes groundbreaking individualized diagnosis and treatment for chronic inflammatory diseases (including COPD and IPF), a very large group of diseases in people aged 50 years or more accounting for 70 percent of all diseases at that age.
global market revenues just for treatment of COPD
forecast for 2031
The significance of stage-specific, personalized diagnosis and treatment
Regenerative Precision Medicine for Chronic Inflammation
A new approach: Chronic inflammation and fibrosis in the aging lung
The future of medicine is individual.
The term presently coined for this is Personalized or Precision Medicine.
Precision medicine is defined by the simultaneous identification (diagnosis) and targeted elimination (treatment) of metabolic defects causing and driving a particular disease at a decisive stage of its manifestation. It relies on clinically validated biomarkers.
In future, biomarkers will directly link diagnosis to treatment (beyond all present clinical, pathological, imaging or laboratory procedures):
- in accordance with the precise stage of metabolic disease development at the time of recording, and
- with an accordingly targeted therapy (based on detailed assessment of the relevant abnormalities in both organ structure and function).
Why so?
Because this combination of biomarker-based diagnosis and the corresponding marker-based treatment permits:
- an unprecedented increase of effectiveness of any given therapy, while, at the same time, resulting in
- a significant reduction of both number and severity of undesired side effects of treatment.
Presently, we are still at the dawn of Precision Medicine.
Primary advances made in the field of tumor disease plainly demonstrate the enormous advantages of Precision Medicine.
However, Precision Medicine applies not only to tumor disease currently accounting for 30 percent of all diseases in people over 50 years of age.
It applies as well to the group of Chronic Inflammatory Diseases representing the majority of diseases in aging populations (accounting for up to 70 percent after the age of 50), and there, Precision Medicine is badly needed.
Maintenance of matrix structures: Significance for healthy aging
Surface and matrix structures create borders within the body and its organs. These borders separate reaction spaces, called the compartments of the body. Intact surface and matrix structures control and guarantee regular organ function by separating potentially hazardous biochemical and biophysical reactions running continually within these compartments.
The body’s membrane structures are many and wide. The more expanded and the more mobile these structures are (for example, to gaseous atmospheres in and around the body or to fluids, like the blood-stream), the more profound the effects of their dissolution.
This process is termed loss of surface integrity. Why is it dangerous?
Because hazardous biochemical and biophysical reactions will run uncontrolled and in the wrong places causing reactive inflammation and need of repair. Once such a loss of surface integrity becomes permanent, both inflammation and need for repair (or in other word:wound healing) will become permanent and progressively intense affecting regular organ function, as organ function relies on the same structures.
Thus, maintenance of matrix structures ensures functional reaction spaces, prevents inflammation, and preserves proper function of organs, i.e. health. This maintenance process is called regenerative repair or primary wound healing. Because of its importance, the body will uphold it over decades, and with considerable effort.
Regenerative repair will only become slow and ineffective, when the metabolic processes necessary to maintain it become ineffective. This is exactly what happens with age.
This explains the danger posed by the combination of persisting loss of surface integrity and progressively declining regenerative repair. Due to this combination, medicine witnesses a steady increase in number and severity of Chronic Inflammatory Diseases in aging societies affecting various organs, such as lung, vascular system, bowels, joints and skin.
The lungs have a surface are a equivalent to a tennis court. With each breath (and just at rest, we breathe roughly 16 times per minute), this huge surface is pulled wide by muscle force and then contracted again only by the elastic structure of the lung.
The biophysical forces put on this lung structure during breathing are considerable. Therefore, the loss of surface (matrix) integrity in structurally and functionally critical lung compartments, such as the small bronchi (the air-conducting space) and the alveoli (the gas-exchanging space) has tremendous effects, inflammation being just its first result.
Not surprisingly, acute pneumonia(pulmonary inflammation) is the most common cause of death in aging individuals - regardless of what other disorder is simultaneously occurring in the body.
Chronic pulmonary inflammation is equally disastrous, but much less apparent, as the body’s regenerative repair capacity (shrinking with age) masks its effects on structure and function. As a result, the critical outcome of chronic inflammation are usually difficult to diagnose before the age of 50. This is unfortunate, because the combined pathology of structural disintegration will become progressive at that stage, as the body has no primary repair capacity anymore to withstand. The result is both renewed inflammation and a different repair quality called secondary repair (i.e. scarring = fibrosis).
While medical and pharmaceutical development has centered on inflammatory processes for many decades, persistent loss of structural integrity combined with a growing inability to sustain regenerative wound healing have only recently gained attention.
Transgenion’s new knowledge concerns the very basis of Precision. Accordingly, our identification process has centered on prospective clinical studies identifying stage-specific biomarkers during the entire course of disease development, e.g. in COPD covering up to 30 years.
Fortunately, this has been possible, as each stage of disease comprises critical periods characterized by clinically well-characterized structural and functional features allowing the correct association with the key biomarkers linking structural failure to inflammation, fibrosis and loss of function.
Not very surprisingly, many of the clinically validated key markers originate from processes controlling and enabling repair.
Currently at Technical Readiness Level 6
1
2
3
4
5
7
8
9
Complete analysis for all clinically relevant markers in lung tissue based on 3-year observation per subject, representing COPD progression over more than 30 years.
The significance of stage-specific, personalized diagnosis and treatment
Regenerative Precision Medicine for Chronic Inflammation
A new approach: Chronic inflammation and fibrosis in the aging lung
The future of medicine is individual.
The term presently coined for this is Personalized or Precision Medicine.
Precision medicine is defined by the simultaneous identification (diagnosis) and targeted elimination (treatment) of metabolic defects causing and driving a particular disease at a decisive stage of its manifestation. It relies on clinically validated biomarkers.
In future, biomarkers will directly link diagnosis to treatment (beyond all present clinical, pathological, imaging or laboratory procedures):
- in accordance with the precise stage of metabolic disease development at the time of recording, and
- with an accordingly targeted therapy (based on detailed assessment of the relevant abnormalities in both organ structure and function).
Why so?
Because this combination of biomarker-based diagnosis and the corresponding marker-based treatment permits:
- an unprecedented increase of effectiveness of any given therapy, while, at the same time, resulting in
- a significant reduction of both number andseverity of undesired side effects of treatment.
Presently, we are still at the dawn of Precision Medicine.
Primary advances made in the field of tumor disease plainly demonstrate the enormous advantages of Precision Medicine.
However, Precision Medicine applies not only to tumor disease currently accounting for 30 percent of all diseases in people over 50 years of age.
It applies as well to the group of Chronic Inflammatory Diseases representing the majority of diseases in aging populations (accounting for up to 70 percent after the age of 50), and there, Precision Medicine is badly needed.
The lesson from our pilot study:
Maintenance of matrix structures and its significance for healthy aging.
Surface and matrix structures create borders within the body and its organs. These borders separate reaction spaces, called the compartments of the body. Intact surface and matrix structures control and guarantee regular organ function by separating potentially hazardous biochemical and biophysical reactions running continually within these compartments.
The body’s surface and matrix structures are many and wide. The more expanded and the more mobile these structures are (for example, to gaseous atmospheres in and around the body or to fluids, like the blood-stream), the more profound the effects of their dissolution.
This process is termed loss of surface integrity. Why is it dangerous?
Because hazardous biochemical and biophysical reactions will run uncontrolled and in the wrong places causing reactive inflammation and need of repair. Once such a loss of surface integrity becomes permanent, both inflammation and need for repair (or in other word: wound healing) will become permanent and progressively intense affecting regular organ function, as organ function relies on the same structures.
Thus, maintenance of matrix structures ensures functional reaction spaces, prevents inflammation, and preserves proper function of organs, i.e. health. This maintenance process is called regenerative repair or primary wound healing. Because of its importance, the body will uphold it over decades, and with considerable effort.
Regenerative repair will only become slow and ineffective, when the metabolic processes necessary to maintain it become ineffective. This is exactly what happens with age.
This explains the danger posed by the combination of persisting loss of surface integrity and progressively declining regenerative repair. Due to this combination, medicine witnesses a steady increase in number and severity of Chronic Inflammatory Diseases in aging societies affecting various organs, such as lung, vascular system, bowels, joints and skin.
The lungs have a surface are a equivalent to a tennis court. With each breath (and just at rest, we breathe roughly 16 times per minute), this huge surface is pulled wide by muscle force and then contracted again only by the elastic structure of the lung.
The biophysical forces put on this lung structure during breathing are considerable. Therefore, the loss of surface (matrix) integrity in structurally and functionally critical lung compartments, such as the small bronchi (the air-conducting space) and the alveoli (the gas-exchanging space) has tremendous effects, inflammation being just its first result.
Not surprisingly, acute pneumonia(pulmonary inflammation) is the most common cause of death in aging individuals - regardless of what other disorder is simultaneously occurring in the body.
Chronic pulmonary inflammation is equally disastrous, but much less apparent, as the body’s regenerative repair capacity (shrinking with age) masks its effects on structure and function. As a result, the critical outcome of chronic inflammation are usually difficult to diagnose before the age of 50. This is unfortunate, because the combined pathology of structural disintegration will become progressive at that stage, as the body has no primary repair capacity anymore to withstand. The result is both renewed inflammation and a different repair quality called secondary repair (i.e. scarring = fibrosis).
While medical and pharmaceutical development has centered on inflammatory processes for many decades, persistent loss of structural integrity combined with a growing inability to sustain regenerative wound healing have only recently gained attention.
Transgenion’s new knowledge concerns the very basis of Precision. Accordingly, our identification process has centered on prospective clinical studies identifying stage-specific biomarkers during the entire course of disease development, e.g. in COPD covering up to 30 years.
Fortunately, this has been possible, as each stage of disease comprises critical periods characterized by clinically well-characterized structural and functional features allowing the correct association with the key biomarkers linking structural failure to inflammation, fibrosis and loss of function.
Not very surprisingly, many of the clinically validated key markers originate from processes controlling and enabling repair.
First-time sequential recording of all relevant markers throughout the entire COPD course (from the risk stage to end-stage).
Unique dataset fully patented (25 patents across US, Europe and Japan).
In summary, this results in a market lead of at least 10 years.
The perfect Blend of Strategic Vision and Practical Execution
Prof. Dr. Rolf Ziesche
Inventor, Founder & CEO
at Transgenion
Upcoming Events
14
17
07
13
Explore how Transgenion is leading a groundbreaking transformation in the battle against COPD and various respiratory conditions.
Chronic Obstructive Pulmonary Disease (COPD)
COPD) is a progressive and debilitating respiratory condition characterized by persistent airflow limitation. This article provides a comprehensive review of COPD, including its description, pathology, epidemiology, and treatment strategies.
Overview of the socioeconomic burden imposed by COPD
The socioeconomic impact of Chronic Obstructive Pulmonary Disease (COPD) is substantial, affecting individuals, families, and healthcare systems worldwide. COPD imposes both direct and indirect costs, encompassing medical expenses, lost productivity, and diminished quality of life.
Inventor of the Year 2016 by Medical University of Vienna
Rolf Ziesche from the Clinical Department of Pulmonology at the University Clinic for Internal Medicine II of the Medical University of Vienna was elected 'Inventor of the Year 2016' by the Medical University of Vienna.
Unique Investment Opportunity
The future of Personalized Medicine for healthy aging has started. Seize this unprecedented opportunity to be a pioneer in the Personalized Medicine movement!
